BlackRock, Inc. 13D and 13G filings for Denali Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-11-08 5:31 pm Unchanged | 2024-09-30 | 13G | Denali Therapeutics Inc. DNLI | BlackRock Inc. BLK | 13,787,873 9.600% | 0 (Unchanged) | Filing |
| 2024-10-21 4:11 pm Purchase | 2024-09-30 | 13G | Denali Therapeutics Inc. DNLI | BlackRock Inc. BLK | 13,787,873 9.600% | 2,245,012 (+19.45%) | Filing |
| 2024-01-25 4:59 pm Purchase | 2023-12-31 | 13G | Denali Therapeutics Inc. DNLI | BlackRock Inc. BLK | 11,542,861 8.400% | 2,221,432 (+23.83%) | Filing |
| 2023-01-31 5:52 pm Purchase | 2022-12-31 | 13G | Denali Therapeutics Inc. DNLI | BlackRock Inc. BLK | 9,321,429 6.900% | 1,210,607 (+14.93%) | Filing |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | Denali Therapeutics Inc. DNLI | BlackRock Inc. BLK | 8,110,822 6.600% | 1,734,744 (+27.21%) | Filing |
| 2021-02-02 2:56 pm Purchase | 2020-12-31 | 13G | Denali Therapeutics Inc. DNLI | BlackRock Inc. BLK | 6,376,078 5.300% | 1,348,764 (+26.83%) | Filing |